Business Description
Founded in 2012 and based in Nanjing, China, Leads Biolabs is a clinical-stage company focused on developing new antibody-based medicines for cancer, autoimmune conditions, and other serious illnesses. Its pipeline includes several promising treatments, such as LBL-024 for a rare form of cancer called extra-pulmonary neuroendocrine carcinoma, LBL-007 aimed at reactivating the immune system's ability to fight tumors, and LBL-034 designed to direct immune cells against cancer. The company has also built two proprietary drug development platforms that support its broader research efforts in creating more effective and safer cancer therapies.
